Longview residents were out in front of the Gregg County Courthouse on Saturday to take part in the Walk to End Alzheimer’s ...

Frontotemporal dementia can be hard to diagnose because while dementia can be part of the illness, it's not a factor in all ...

The brain has a waste-disposal system that clears away junk proteins that contribute to the development of dementia and ...

Sage Therapeutics said on Tuesday it will discontinue the development of its Alzheimer's disease drug as it did not meet the ...

The brain has a waste-disposal system that clears away junk proteins that contribute to the development of dementia an ...

Sage has decided to discontinue the development of dalzanemdor in Alzheimer’s disease. A study of the candidate in Huntington ...

Researchers in China reported finding β-amyloid (Aβ) deposits along the ocular glymphatic system in patients with Alzheimer's ...

Saturday marked the 16th year for the Walk to End Alzheimer’s here in Victoria, however, the fight for the disease has been ...

Sage Therapeutics does not plan further clinical development of its dalzanemdor drug candidate in Alzheimer's disease following its failure in a mid-stage study.

Muscae volitantes — “eye floaters” are those little, transparent threads that you see floating across your eyeball. Generally ...

(RTTNews) - Sage Therapeutics, Inc. (SAGE) Tuesday said its Phase 2 LIGHTWAVE study to evaluate dalzanemdor in participants with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's ...

Sage Therapeutics said on Tuesday it would discontinue the development of its experimental drug for Alzheimer's disease as it ...